Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSeres Therapeutics Inc

Seres Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.98 USD -0.11 ( 5.26%)
Last update at 2026-11-06T21:25:00Z
VOLUME
82279
Market Cap
65.14M

Momentum Score

…

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.96
Low
2.26
High
52 Week Price Range
6.53
Low
30.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Seres Therapeutics is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapeutics intended to restore or modulate the gut microbiome for gastrointestinal and systemic diseases. Long-term growth may be driven by progress in its clinical pipeline, scientific interest in the microbiome, potential regulatory approvals and commercial partnerships, and expanding indications, which could make it attractive to investors seeking exposure to novel therapeutic modalities.
Key risks include binary clinical and regulatory outcomes, significant cash burn and the need for additional financing, intense competition and scientific uncertainty around microbiome therapeutics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.09
Dividend Yield
-
Revenue TTM
126.33M
Revenue Per Share
0.87
Gross Profit TTM
-18.05M
Debt / Equity
6.65
ROE
-1556.28%
Net Debt
60.85M
ROCE
-250.02%
Diluted EPS TTM
-7.95

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -250.16M -65.58M -89.13M -70.28M -98.94M
Net income -253.82M -61.50M -86.45M -64.24M -98.94M
Selling general administrative 79.69M 69.26M 30.77M 24.75M 32.60M
Gross profit 6.12M 143.19M 33.22M 34.51M 28.27M
Reconciled depreciation 6.63M 5.95M 6.58M 7.60M 7.86M
Ebit -246.49M -64.49M -88.13M -71.88M -108.15M
Ebitda -244.14M -62.67M -86.20M -68.28M -100.28M
Depreciation and amortization 2.35M 1.82M 1.93M 3.59M 7.86M
Non operating income net other 2.35M 1.82M 1.93M 2.10M 0.17M
Operating income -246.49M -64.49M -88.13M -71.88M -100.28M
Other operating expenses 253.62M 209.42M 121.34M 104.89M 128.55M
Interest expense 6.02M 2.91M 2.92M 0.50M 1.17M
Interest income 3.06M 2.87M 0.95M 1.03M 1.17M
Net interest income -2.96M -0.04M -1.98M 0.53M 1.17M
Non recurring - - - 1.49M -
Income tax expense 3.67M -4.08M -2.67M -6.04M 1.34M
Total revenue 7.13M 144.93M 33.22M 34.51M 28.27M
Total operating expenses 253.62M 209.42M 121.34M 104.89M 128.55M
Cost of revenue 1.00M 1.73M - 80.14M 95.95M
Total other income expense net -3.67M -1.08M -1.00M 1.60M 0.17M
Net income from continuing ops -250.16M -65.58M -89.13M -70.28M -98.94M
Net income applicable to common shares -250.16M -65.58M -89.13M -70.28M -98.94M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 139.81M 358.60M 348.78M 354.86M 342.94M
Other current assets 3.13M 9.12M 13.42M 12.92M 5.77M
Total liab 126.03M 403.46M 338.00M 223.35M 168.19M
Total stockholder equity 13.78M -44.86M 10.78M 131.51M 174.75M
Other current liab 28.47M 80.61M 59.84M 45.09M 14.23M
Common stock 0.17M 0.14M 0.12M 0.09M 0.09M
Capital stock 0.17M 0.14M 0.12M 0.09M 0.09M
Retained earnings -978.10M -978.24M -864.51M -614.35M -548.78M
Other liab - - 93.87M 98.49M 86.58M
Other assets - - 20.05M 14.59M 60.27M
Cash 30.79M 127.97M 163.03M 180.00M 116.05M
Total current liabilities 41.22M 98.66M 85.60M 82.26M 46.41M
Current deferred revenue - 7.73M 4.26M 16.82M 22.60M
Net debt 60.85M 85.97M -0.44M -130.79M -75.28M
Short term debt 8.67M 6.68M 4.06M 6.61M 5.57M
Short long term debt - - 0.46M - 0.45M
Short long term debt total 91.64M 213.94M 162.59M 49.21M 40.77M
Other stockholder equity 991.71M 933.24M 875.18M 745.83M 723.48M
Property plant equipment - - 22.98M 36.15M 13.90M
Total current assets 38.67M 175.41M 194.76M 303.63M 268.78M
Long term investments - - 0.00M 0.49M 49.83M
Net tangible assets - - 10.78M 131.51M 174.75M
Short term investments - 0.00M 18.31M 110.70M 137.57M
Net receivables 4.75M 8.67M - 0.00M 9.39M
Long term debt - 101.54M 50.59M 24.64M 24.64M
Inventory - 29.65M - - -
Accounts payable 4.08M 3.64M 17.44M 13.73M 4.02M
Accumulated other comprehensive income - - -0.01M -0.06M -0.05M
Common stock total equity - - 0.12M 0.09M 0.09M
Retained earnings total equity - - -864.51M -614.35M -548.78M
Non currrent assets other 8.70M 41.35M 20.05M 14.59M 1.40M
Non current assets total 101.14M 183.19M 154.02M 51.23M 74.16M
Capital lease obligations 91.64M 112.39M 111.54M 24.57M 15.68M
Long term debt total - - 50.59M 24.64M 24.64M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 92.25M 73.65M -158.30M -29.52M 114.25M
Change to liabilities 2.20M 5.00M 2.61M -4.37M 0.38M
Total cashflows from investing activities 82.43M 64.09M -158.89M -30.52M 112.32M
Net borrowings 25.70M -0.95M -0.95M 24.57M 25.00M
Total cash from financing activities 129.60M 1.18M 303.42M 86.23M 0.27M
Change to operating activities -13.47M 27.14M -2.87M -3.86M -1.32M
Net income -250.16M -65.58M -89.13M -70.28M -98.94M
Change in cash -16.79M 71.95M 50.92M -20.81M 49.73M
Begin period cash flow 188.00M 116.05M 65.13M 85.93M 36.20M
End period cash flow 171.22M 188.00M 116.05M 65.13M 85.93M
Total cash from operating activities -228.82M 6.69M -93.61M -76.52M -62.85M
Issuance of capital stock 101.17M 0.00M 268.64M 61.22M 0.06M
Depreciation 6.63M 5.95M 6.58M 7.60M 7.86M
Other cashflows from investing activities - - - -29.52M 114.25M
Change to inventory - 27.14M -2.87M -3.86M -
Change to account receivables 0.00M 9.39M -7.60M -1.78M -1.78M
Sale purchase of stock 99.46M 2.13M 258.63M 60.97M -0.20M
Other cashflows from financing activities 30.34M 1.30M 34.78M 25.02M 0.40M
Change to netincome 25.48M 24.29M 8.82M 8.73M 16.64M
Capital expenditures 9.82M 9.57M 0.59M 1.00M 1.94M
Change receivables - 9.39M -7.60M -1.78M -
Cash flows other operating -14.37M -18.70M -15.89M -16.25M 11.42M
Cash and cash equivalents changes -16.79M 71.95M 50.92M -20.81M 49.73M
Change in working capital -18.39M 41.53M -23.20M -24.63M 11.80M
Stock based compensation 25.48M 20.22M 8.82M 8.34M 16.64M
Other non cash items 7.62M 2.04M 3.31M 2.34M -0.21M
Free cash flow -238.64M -2.88M -94.20M -77.52M -64.79M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MCRB
Seres Therapeutics Inc		 -0.11
5.26%		 1.98 - 3.97 390.27 1.29 805.87 -2.07
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Seres Therapeutics Inc

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

101 Cambridgepark Drive, Cambridge, MA, United States, 02140

617 945 9626

https://www.serestherapeutics.com

103

Name Title Year Born
Mr. Eric D. Shaff M.B.A. Pres, CEO & Director 1976
Mr. David A. Arkowitz M.B.A. Exec. VP, CFO & Head of Bus. Devel. 1961
Dr. Matthew R. Henn Ph.D. Exec. VP & Chief Scientific Officer 1975
Dr. David S. Ege Ph.D. Exec. VP & Chief Technology Officer 1974
Mr. Carlo Tanzi Ph.D. Investor Relations Officer NA
Mr. Thomas J. DesRosier Esq., J.D. Chief Legal Officer, Exec. VP & Sec. 1955
Ms. Kristin Ainsworth Sr. VP of Corp. Communications NA
Mr. Jeff York VP of HR NA
Ms. Paula A. Cloghessy SHRM-SCP, SPHR Exec. VP & Chief People Officer 1972
Dr. Lisa von Moltke M.D. Exec. VP & Chief Medical Officer 1959

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…